Data from 2 international, double-blind, placebo-controlled trials showed that cenobamate, a voltage-gated sodium channel blocker, has consistent, statistically significant, and clinically meaningful antiepileptic efficacy . Treatment-emergent adverse events (AEs) were dose dependent and generally mild or moderate.
The 2 pivotal trials were named C013 and C017. They enrolled adult patients with uncontrolled focal onset seizures (FOS) with ≥3 seizures per month (C013) or ≥8 seizures per 8 weeks (C017). Participants also used 1-3 concomitant anti-epileptic drugs. In C013 they were randomised to cenobamate 200 mg/day or placebo; in C017 to cenobamate 100, 200, or 400 mg/day, or placebo. Response was defined as ≥50% reduction in seizure frequency from baseline.
In C013, responder rate in the maintenance phase was significantly h...
please login to read the entire article:
You need to register to read the entire article, please do so now.
« How genetic testing can contribute to epilepsy management Next Article
Sustained seizure reductions with cannabidiol for Lennox-Gastaut syndrome »
Table of Contents: EAN 2020
Headache and Pain
Neuromyelitis Optica Spectrum Disorder
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.